Group 1: Company Strategy and Development - The company focuses on the research and development of chronic disease medications, including diabetes and cardiovascular diseases, aiming to improve the quality of life and medication safety for patients [3] - The company seeks to integrate its products with mobile internet for data management and application, expanding its service and product lines to cover chronic disease management [3] - The goal is to enhance the company's international market presence and brand recognition through capital operations in international markets [3] Group 2: Financial Performance - In the first half of 2015, the company achieved operating revenue of 265 million CNY, a year-on-year increase of approximately 69% [3] - The net profit attributable to shareholders was 89.68 million CNY, reflecting a year-on-year growth of about 82% [3] - The growth is attributed to effective product market promotion and steady development of various product lines [3] Group 3: Product Development and Regulatory Progress - The company’s new product, Eptifibatide, received drug registration approval and a new drug certificate in January 2015, with production scheduled to commence [4] - Eptifibatide is recognized as a first-line drug for antiplatelet therapy in coronary heart disease and is expected to significantly enhance the company's performance [4] - The company has made progress in international registrations, with several products obtaining necessary approvals and awaiting inspections [4] Group 4: Strategic Partnerships and Innovations - The company signed a strategic cooperation agreement with a U.S. pharmaceutical company to advance the development of a key product, enhancing its international market strategy [4] - A strategic framework agreement was established with Tencent to accelerate the wireless and network integration of its non-invasive continuous glucose monitoring system [5] - This partnership aims to improve user experience and expand market influence in the IoT and smart measurement product sectors [5]

Group 1: Company Overview - The company is Shenzhen Hanyu Pharmaceutical Co., Ltd., with stock code 300199 and abbreviation Hanyu Pharmaceutical [1]. Group 2: Investor Relations Activities - The investor relations activity took place on September 15, 2015, from 10:00 AM to 12:00 PM [2]. - Participants included representatives from various investment firms such as GF Fund, Changxin Fund, and others [2]. Group 3: Drug Approval and R&D Impact - Recent reforms in drug approval processes are expected to accelerate the speed of new product launches for the company [3]. - The company has several products in the registration process, with dozens of items currently under registration [3]. - The drug Eptifibatide, which took 10 years from project initiation to approval, is a significant new drug that will positively impact the company's performance [3]. Group 4: Future Product Launches - The company anticipates launching two new products in the coming years, which are expected to contribute significantly to revenue growth [3]. - The company has made steady progress in international product registrations, with several products undergoing FDA inspections [3]. Group 5: Strategic Collaborations - A strategic cooperation agreement was signed with Akorn Pharmaceuticals for the development of Acetylglutamyl, which is expected to enhance the company's international market presence [4]. - The collaboration aims to improve the company's brand recognition and expand its international sales framework [4]. Group 6: Innovative Products - The company is developing a non-invasive continuous glucose monitoring device, GlucoPred, which has received approval for Phase III clinical trials in Norway [4]. - The device aims to improve the quality of life for diabetes patients by providing real-time glucose data and reducing the risk of long-term complications [4].

证券代码: 300199 证券简称:翰宇药业 深圳翰宇药业股份有限公司 投资者关系活动记录表 编号: 2014-006 | --- | --- | --- | |------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | 口亦镇说明会 | | 活动类别 | 口新闻发布会 | ...

证券简称:翰宇药业 证券代码: 300199 深圳翰宇药业股份有限公司 投资者关系活动记录表 编号:2015-015 | --- | --- | --- | --- | --- | |-------------------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | i 区特定对象调研 | □分析师会议 | | | | 投资者关系 | □媒体采访 | □业绩说明会 | | | | 活动类别 | □新闻发布会 | 口路演活动 | | | | | □现场参观 | | | | | | □其他:投资者恳谈会 | | | | | 参与单位名称 及人员姓名 | | 國泰投信(國泰金控)陈秋婷、申万宏源（香港） 陈世杰 | | | | 时间 ...

Group 1: Fundraising and Investment Plans - The company has approved a non-public offering of shares, pending shareholder approval and submission to the China Securities Regulatory Commission [2] - Funds raised will enhance R&D capabilities, focusing on innovation in drug formulation and delivery methods to strengthen industry position [2] - The funds will also support the "Internet + Chronic Disease Management Platform" and marketing network construction, aiming to expand product promotion and establish a data-driven service platform for chronic disease patients [3] Group 2: R&D Investment and Strategy - The company maintains an annual R&D investment ratio of approximately 10% of sales revenue, positioning itself as a leader in the peptide drug sector [3] - Ongoing efforts include enhancing R&D capabilities, protecting intellectual property, and increasing product development for domestic and international markets [3] - The company is in the early stages of large-scale product launches, with expectations for continued increases in R&D investment [3] Group 3: Product Development and Collaborations - The clinical trials for a non-invasive continuous glucose monitoring device in collaboration with Pudi Medical are progressing well, with EU certification expected by November [3] - Following EU certification, the company plans to apply for market access in Hong Kong and Macau, and will seek approval from the National Medical Products Administration in China [3]